MCID: PNC008
MIFTS: 39

Pancreatic Endocrine Carcinoma

Categories: Cancer diseases, Endocrine diseases, Neuronal diseases

Aliases & Classifications for Pancreatic Endocrine Carcinoma

MalaCards integrated aliases for Pancreatic Endocrine Carcinoma:

Name: Pancreatic Endocrine Carcinoma 12 15 17 71
Malignant Neoplasm of Islets of Langerhans 12
Pancreatic Neuroendocrine Carcinoma 12
Carcinoma of Endocrine Pancreas 12
Carcinoma, Islet Cell 43
Islet Cell Carcinoma 12
Carcinoma Islet Cell 54

Classifications:



External Ids:

Disease Ontology 12 DOID:1798
ICD9CM 34 157.4
MeSH 43 D018273
NCIt 49 C3770
SNOMED-CT 67 60346004
ICD10 32 C25.4
UMLS 71 C1328479

Summaries for Pancreatic Endocrine Carcinoma

Disease Ontology : 12 An islet cell tumor that has material basis in epithelial cells.

MalaCards based summary : Pancreatic Endocrine Carcinoma, also known as malignant neoplasm of islets of langerhans, is related to glucagonoma and peptic ulcer disease. An important gene associated with Pancreatic Endocrine Carcinoma is MEG3 (Maternally Expressed 3), and among its related pathways/superpathways are Peptide ligand-binding receptors and Relaxin signaling pathway. The drugs Fentanyl and Sunitinib have been mentioned in the context of this disorder. Affiliated tissues include pancreas, liver and breast.

Related Diseases for Pancreatic Endocrine Carcinoma

Diseases related to Pancreatic Endocrine Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 328)
# Related Disease Score Top Affiliating Genes
1 glucagonoma 30.4 SST GAST CHGA
2 peptic ulcer disease 30.1 SST MEN1 GAST
3 ampulla of vater neoplasm 30.0 SYP SST CHGA
4 somatostatinoma 29.9 SSTR2 SST SPINK5 PPY MEN1 GCG
5 hyperparathyroidism 29.7 PTHLH MEN1 GAST CHGA
6 carcinoid syndrome 29.7 SYP SST MEN1 CHGA
7 large cell carcinoma 29.7 SYP PTHLH NCAM1 CHGA
8 merkel cell carcinoma 29.7 SYP SST NCAM1 CHGA
9 primary hyperparathyroidism 29.6 PTHLH MEN1 GAST CHGA
10 lung large cell carcinoma 29.6 SYP SPINK5 NCAM1 CHGA
11 acinar cell carcinoma 29.4 SYP SERPINA3 GAST CHGA AFP
12 acromegaly 29.2 SSTR5 SSTR3 SSTR2 SST MEN1
13 pheochromocytoma 29.0 SYP SST NCAM1 MEN1 MEG3 CHGA
14 carcinoid tumors, intestinal 28.9 SYP SSTR2 SST MEN1 GAST CHGA
15 insulinoma 28.7 SSTR5 SSTR2 SST MEN1 GCG GAST
16 gastrinoma 28.6 SYP SSTR5 SSTR2 SST MEN1 GAST
17 zollinger-ellison syndrome 28.5 SST PPY MEN1 GAST CHGA
18 islet cell tumor 28.4 SYP SSTR2 SST SPINK5 SERPINA3 PTHLH
19 vipoma 28.3 SSTR3 SST SPINK5 MEN1 GAST CHGA
20 pancreatic cancer 28.2 SSTR2 SST SERPINA3 PTHLH MEN1 MEG3
21 neuroendocrine carcinoma 28.1 SYP SST NCAM1 MEN1 GCG GAST
22 neuroendocrine tumor 27.9 SYP SSTR2 SST NCAM1 MEN1 GCG
23 pancreatic cholera 27.6 SST SPINK5 PPY MEN1 GCG GAST
24 multiple endocrine neoplasia, type i 27.2 SYP SST SPINK5 PPY MEN1 GCG
25 neuroendocrine carcinoma of pancreas 11.4
26 lung combined type small cell carcinoma 10.5 SYP NCAM1
27 hypoganglionosis 10.5 SYP NCAM1
28 glomangiosarcoma 10.5 SYP NCAM1
29 cerebellopontine angle primitive neuroectodermal tumor 10.5 SYP NCAM1
30 orbital cancer 10.4 SYP NCAM1
31 pineal region teratoma 10.4 SYP AFP
32 nasal cavity olfactory neuroblastoma 10.4 SYP NCAM1
33 thymus sarcomatoid carcinoma 10.4 SYP AFP
34 adult type testicular granulosa cell tumor 10.4 NCAM1 AFP
35 non-gestational ovarian choriocarcinoma 10.4 NCAM1 AFP
36 ectopic cushing syndrome 10.4 SYP SST
37 prostate stromal sarcoma 10.4 SYP NCAM1
38 infected hydrocele 10.4 NCAM1 AFP
39 ovarian germ cell teratoma 10.4 SYP AFP
40 biliary tract benign neoplasm 10.4 NCAM1 AFP
41 gastric antral vascular ectasia 10.4 SST GAST
42 lethal midline granuloma 10.3 SERPINA3 NCAM1
43 gastrointestinal lymphoma 10.3 SERPINA3 NCAM1
44 meningothelial meningioma 10.3 SSTR2 SERPINA3
45 nelson syndrome 10.3 SSTR5 SSTR2 SST
46 mixed hepatoblastoma 10.3 SERPINA3 AFP
47 dysgerminoma of ovary 10.3 PTHLH AFP
48 giant hemangioma 10.3 SERPINA3 AFP
49 breast neuroendocrine neoplasm 10.3 SYP CHGA
50 scrotum neoplasm 10.3 SERPINA3 AFP

Graphical network of the top 20 diseases related to Pancreatic Endocrine Carcinoma:



Diseases related to Pancreatic Endocrine Carcinoma

Symptoms & Phenotypes for Pancreatic Endocrine Carcinoma

Drugs & Therapeutics for Pancreatic Endocrine Carcinoma

Drugs for Pancreatic Endocrine Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 93)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
2
Sunitinib Approved, Investigational Phase 3 557795-19-4, 341031-54-7 5329102
3
leucovorin Approved Phase 2, Phase 3 58-05-9 6006 143
4
Fluorouracil Approved Phase 2, Phase 3 51-21-8 3385
5
Oxaliplatin Approved, Investigational Phase 2, Phase 3 61825-94-3 43805 6857599 5310940 9887054
6
Levoleucovorin Approved, Investigational Phase 2, Phase 3 68538-85-2
7
Bevacizumab Approved, Investigational Phase 2, Phase 3 216974-75-3
8
Folic acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 59-30-3 6037
9 Pancreatic Polypeptide Investigational Phase 2, Phase 3 59763-91-6
10 Liver Extracts Phase 3
11 Cola Phase 3
12 Anesthetics Phase 3
13 Narcotics Phase 3
14 Analgesics Phase 3
15 Analgesics, Opioid Phase 3
16 Anesthetics, General Phase 3
17 Anesthetics, Intravenous Phase 3
18 Angiogenesis Inhibitors Phase 3
19 Immunosuppressive Agents Phase 2, Phase 3
20 Immunologic Factors Phase 2, Phase 3
21 Micronutrients Phase 2, Phase 3
22 Trace Elements Phase 2, Phase 3
23 Vitamins Phase 2, Phase 3
24 Antidotes Phase 2, Phase 3
25 Vitamin B Complex Phase 2, Phase 3
26 Folate Phase 2, Phase 3
27 Nutrients Phase 2, Phase 3
28 Vitamin B9 Phase 2, Phase 3
29 Protective Agents Phase 2, Phase 3
30 Antimetabolites Phase 2, Phase 3
31 Antineoplastic Agents, Immunological Phase 2, Phase 3
32
Palbociclib Approved, Investigational Phase 2 571190-30-2 5005498 11431660 5330286
33
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
34
Clotrimazole Approved, Vet_approved Phase 2 23593-75-1 2812
35
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
36
Gefitinib Approved, Investigational Phase 2 184475-35-2 123631
37
Streptozocin Approved, Investigational Phase 2 18883-66-4 29327
38
Melphalan Approved Phase 2 148-82-3 460612 4053
39
Cisplatin Approved Phase 2 15663-27-1 2767 441203 84093
40
Carboplatin Approved Phase 2 41575-94-4 10339178 38904 498142
41
Etoposide Approved Phase 2 33419-42-0 36462
42
Ipilimumab Approved Phase 2 477202-00-9
43
nivolumab Approved Phase 2 946414-94-4
44
Everolimus Approved Phase 2 159351-69-6 70789204 6442177
45
Irinotecan Approved, Investigational Phase 2 97682-44-5, 100286-90-6 60838
46
Pancrelipase Approved, Investigational Phase 2 53608-75-6
47
Lenograstim Approved, Investigational Phase 2 135968-09-1
48
Sargramostim Approved, Investigational Phase 2 83869-56-1, 123774-72-1
49
Sirolimus Approved, Investigational Phase 2 53123-88-9 5284616 6436030 46835353
50
Romidepsin Approved, Investigational Phase 2 128517-07-7 5352062

Interventional clinical trials:

(show top 50) (show all 54)
# Name Status NCT ID Phase Drugs
1 A Randomized, Double-blind, Placebo-controlled Multi-center Study to Evaluate the Safety and Efficacy of Fentanyl Sublingual Spray (Fentanyl SL Spray) for the Treatment of Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
2 A Phase III Randomized, Double-Blind Study Of Sunitinib (SU011248, SUTENT) Versus Placebo In Patients With Progressive Advanced/Metastatic Well-Differentiated Pancreatic Islet Cell Tumors Terminated NCT00428597 Phase 3 sunitinib malate;Placebo
3 A Pilot Study of FOLFOX in Combination With Bevacizumab in Patients With Advanced Neuroendocrine Tumors Terminated NCT00227617 Phase 2, Phase 3 5-fluorouracil;leucovorin;oxaliplatin
4 A Phase 2, Multicenter, Two Tier Study of IMC-A12 in Combination With Depot Octreotide in Patients With Metastatic, Well or Moderately Differentiated Carcinoid or Islet Cell Carcinoma Completed NCT00781911 Phase 2 depot octreotide
5 An Open Label, Stratified, Single-arm Phase II Study of Everolimus in Patients With Advanced Pancreatic Neuroendocrine Tumor (NET) After Failure of Cytotoxic Chemotherapy Completed NCT00363051 Phase 2 Everolimus 10 mg;Octreotide Depot
6 A Phase 2 Study of GW786034 (Pazopanib) in Advanced Low-Grade or Intermediate-Grade Neuroendocrine Carcinoma Completed NCT00454363 Phase 2 Pazopanib Hydrochloride
7 Phase II Study of RAD001 Plus Octreotide Depot in Patients With Metastatic or Unresectable Low Grade Neuroendocrine Carcinoma (Carcinoid, Islet Cell) Completed NCT00113360 Phase 2 RAD001;Octreotide Depot
8 A Phase II Trial to Assess the Activity and Safety of Palbociclib in Patients With Well and Moderately Differentiated Metastatic Pancreatic Neuroendocrine Tumors (pNET) Completed NCT02806648 Phase 2 Palbociclib
9 A Phase II Trial of Bay 43-9006 in Progressive Metastatic Neuroendocrine Tumors Completed NCT00131911 Phase 2 sorafenib tosylate
10 A Phase 2 Trial of Temsirolimus and Bevacizumab in Patients With Endometrial, Ovarian, Hepatocellular Carcinoma, Carcinoid or Islet Cell Cancer Completed NCT01010126 Phase 2 Temsirolimus
11 A Phase II Study of CCI-779 in Metastatic Neuroendocrine Carcinomas Completed NCT00093782 Phase 2 temsirolimus
12 A Phase II Trial of ZD1839 (Iressa®) in Metastatic Neuroendocrine Tumors Completed NCT00075439 Phase 2 gefitinib
13 Perfusion CT as Predictive Biomarker in a Phase II Study of Ziv-Aflibercept in Patients With Advanced Pancreatic Neuroendocrine Tumors Completed NCT02101918 Phase 2
14 Phase II Trial Of Thalidomide In Patients With Low Grade Neuroendocrine Tumors (Carcinoid and Islet Cell Cancers) Completed NCT00027638 Phase 2 thalidomide
15 A Randomised Phase II Study Comparing Capecitabine Plus Streptozocin With or Without Cisplatin Chemotherapy as Treatment for Unresectable or Metastatic Neuroendocrine Tumors Completed NCT00602082 Phase 2 capecitabine;cisplatin;streptozocin
16 A Phase II Study of Isolated Hepatic Perfusion (IHP) With Melphalan for Metastatic Unresectable Cancers of the Liver Completed NCT00019786 Phase 2 isolated perfusion;melphalan
17 Study of First-Line Therapy Comprising Leucovorin Calcium, Fluorouracil, and Irinotecan (FOLFIRI) in Patients With Progressive Locally Advanced or Metastatic Duodenal-Pancreatic Endocrine Tumors Completed NCT00416767 Phase 2 fluorouracil;irinotecan hydrochloride;leucovorin calcium
18 A Phase II Clinical and Biologic Study of AMG 706 and Octreotide in Patients With Low-Grade Neuroendocrine Tumors Completed NCT00427349 Phase 2 AMG 706;octreotide
19 A Phase II Study Of Hepatic Arterial Infusion Of Melphalan With Venous Filtration Via Peripheral Hepatic Perfusion (PHP) For Unresectable Primary And Metastatic Cancers Of The Liver Completed NCT00096083 Phase 2 isolated perfusion;melphalan
20 Antitumor Efficacy of Peptide Receptor Radionuclide Therapy With 177Lutetium -Octreotate Randomized vs Sunitinib in Unresectable Progressive Well-differentiated Neuroendocrine Pancreatic Tumor: First Randomized Phase II. Recruiting NCT02230176 Phase 2 Sunitinib;177Lu-DOTA0-Tyr3-Octreotate
21 Phase 2 Single-Arm Study of Nanoliposomal Irinotecan With Fluorouracil and Leucovorin in Refractory Advanced High Grade Neuroendocrine Cancer of GI, Unknown or Pancreatic Origin Recruiting NCT03736720 Phase 2 Fluorouracil;Leucovorin;Liposomal Irinotecan
22 Randomized Phase II Study of Cisplatin and Etoposide Versus Temozolomide and Capecitabine in Patients With Advanced G3 Non-small Cell Gastroenteropancreatic Neuroendocrine Carcinomas Recruiting NCT02595424 Phase 2 Capecitabine;Carboplatin;Cisplatin;Etoposide;Temozolomide
23 DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors Recruiting NCT02834013 Phase 2
24 A Phase II Study of MLN0128 (TAK-228) in Rapalog-Resistant Advanced Pancreatic Neuroendocrine Tumors (PNET) Active, not recruiting NCT02893930 Phase 2 Sapanisertib
25 Phase II Study of Single Agent Regorafenib in Patients With Advanced/Metastatic Neuroendocrine Tumors Active, not recruiting NCT02259725 Phase 2 regorafenib
26 A Phase 2 Study of Capecitabine, Temozolomide and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors Active, not recruiting NCT01525082 Phase 2 capecitabine;temozolomide
27 Randomized Phase II Study of Everolimus Alone Versus Everolimus Plus Bevacizumab in Patients With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors Active, not recruiting NCT01229943 Phase 2 Everolimus;Octreotide Acetate
28 A Phase I/II Study of the Combination of Temozolomide and Pazopanib in Advanced Pancreatic Neuroendocrine Tumors (PNET) Active, not recruiting NCT01465659 Phase 1, Phase 2 temozolomide;pazopanib hydrochloride
29 A Randomized Phase II Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors Active, not recruiting NCT01824875 Phase 2 temozolomide;capecitabine
30 Phase II Trial of FOLFIRINOX in Metastatic High Grade Gastroenteropancreatic Neuroendocrine Carcinomas Terminated NCT03042780 Phase 2 FOLFIRINOX;Granulocyte colony-stimulating factor (G-CSF)
31 A Randomized, Double-Blinded, Placebo-Controlled Phase II Study of Adjuvant Everolimus Following the Resection of Metastatic Pancreatic Neuroendocrine Tumors to the Liver Terminated NCT02031536 Phase 2 everolimus
32 Phase II Study of Depsipeptide in Metastatic Neuroendocrine Tumors Terminated NCT00084461 Phase 2 romidepsin
33 Phase II Evaluation of Real-Time, Pharmacokinetically Guided Everolimus in Patients With Hormone Receptor Positive Breast Cancer, Pancreatic Neuroendocrine Tumors (PNET), and Renal Cell Carcinoma Terminated NCT02273752 Phase 2 Everolimus
34 Clinical Trial of Sir-Spheres® in Patients With Symptomatic or Progressive Hepatic Metastases From Neuroendocrine Tumors Terminated NCT00466856 Phase 2 octreotide acetate
35 Phase II Study of Vatalanib and Octreotide in Patients With Progressive Low-Grade Neuroendocrine Tumors Withdrawn NCT00227773 Phase 2 octreotide acetate;vatalanib
36 Phase II Study of Antineoplastons A10 and AS2-1 in Patients With Metastatic or Incurable Neuroendocrine Tumors Withdrawn NCT00003514 Phase 2 antineoplaston A10;antineoplaston AS2-1
37 Phase II Study of Dovitinib (TKI-258) in Progressive, Well-Differentiated Pancreatic Neuroendocrine Tumors With and Without Prior VEGF-Inhibitor Therapy Withdrawn NCT02108782 Phase 2 dovitinib lactate
38 Phase I Clinical Trial of Temsirolimus and Vinorelbine in Advanced Solid Tumors. Completed NCT01155258 Phase 1 temsirolimus;vinorelbine ditartrate
39 Phase I Study of Anti-IGF-1R Monoclonal Antibody, IMC-A12, and mTOR Inhibitor, Everolimus, in Advanced Low to Intermediate Grade Neuroendocrine Carcinoma Completed NCT01204476 Phase 1 Everolimus;Octreotide Acetate
40 A Phase I Trial of Herceptin and Interleukin-12 Completed NCT00004074 Phase 1
41 A Phase I Trial of the mTOR Inhibitor RAD001 in Combination With VEGF Receptor Tyrosine Kinase Inhibitor PTK787/ZK 222584 in Patients With Advanced Solid Tumors Completed NCT00655655 Phase 1 everolimus;vatalanib
42 A Phase I Study of Intraperitoneal Oxaliplatin Alone and in Combination With Intraperitoneal Floxuridine and Leucovorin in Patients With Advanced Metastatic Cancer Confined to the Peritoneal Cavity Completed NCT00005860 Phase 1 floxuridine;leucovorin calcium;oxaliplatin
43 A Phase I, Open Label, Maximum Tolerated Dose-Finding Study to Evaluate the Safety and Tolerability of 90Y-DOTA-tyr3-Octreotide Administered by Intravenous Infusion to Children With Refractory Somatostatin-Receptor Positive Tumors Completed NCT00049023 Phase 1
44 A Phase I, Open-Label, Maximum Tolerated Single-Cycle and Four-Cycle Dose-Finding Study to Evaluation the Safety and Tolerability of 90Y-SMT 487 Administered by Intravenous Infusion to Subjects With Refractory Somatostatin-Receptor Positive Tumors Completed NCT00006368 Phase 1
45 A Phase I, Pharmacokinetic, and Biologic Correlative Study of R115777 (NSC 702818) and Herceptin in Patients With Advanced Cancer Completed NCT00005842 Phase 1 tipifarnib
46 A Phase Ib Clinical Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Metastatic Pancreatic Adenocarcinoma Active, not recruiting NCT02231723 Phase 1 BBI608;Nab-paclitaxel;Gemcitabine;Oxaliplatin;Leucovorin;Irinotecan;Fluorouracil;MM-398
47 A Phase I Study of [111In-DTPA-D-Phe]-Octreotide in Patients With Refractory Malignancies Expressing Somatostatin Receptors Terminated NCT00002947 Phase 1
48 A Phase 1 Study of Veliparib (ABT-888) in Combination With Capecitabine and Temozolomide in Advanced Well-Differentiated Neuroendocrine Tumors Withdrawn NCT02831179 Phase 1 Capecitabine;Temozolomide;Veliparib
49 An Open-label Sunitinib Malate (su011248) Continuation Protocol For Patients Who Have Completed A Prior Sunitinib Study And Are Judged By The Investigator To Have The Potential To Benefit From Sunitinib Treatment Completed NCT00428220 sunitinib
50 A Pilot Study to Identify Potential Molecular Predictors of Response to Novel Therapies in Metastatic Pancreatic Neuroendocrine Tumors Completed NCT01603004

Search NIH Clinical Center for Pancreatic Endocrine Carcinoma

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Dacarbazine

Cochrane evidence based reviews: carcinoma, islet cell

Genetic Tests for Pancreatic Endocrine Carcinoma

Anatomical Context for Pancreatic Endocrine Carcinoma

MalaCards organs/tissues related to Pancreatic Endocrine Carcinoma:

40
Pancreas, Liver, Breast, Pancreatic Islet, Endothelial, Lung, Bone

Publications for Pancreatic Endocrine Carcinoma

Articles related to Pancreatic Endocrine Carcinoma:

(show top 50) (show all 152)
# Title Authors PMID Year
1
Long Survival and Prolonged Remission after Surgery and Chemotherapy in a Metastatic Mismatch Repair Deficient Pancreatic Neuroendocrine Carcinoma with MLH1/PMS2 Immunodeficiency and Minimal Microsatellite Shift. 61
32388775 2020
2
Unexpected response to palliative radiotherapy for subcutaneous metastases of an advanced small cell pancreatic neuroendocrine carcinoma: a case report of two different radiation schedules. 61
32293342 2020
3
Nonfunctional Pancreatic Neuroendocrine Carcinoma With Isolated Retroperitoneal Metastasis: A Case Report and Literature Review. 61
32101939 2020
4
RBL1 (p107) functions as tumor suppressor in glioblastoma and small-cell pancreatic neuroendocrine carcinoma in Xenopus tropicalis. 61
32001819 2020
5
Validation and modification of staging Systems for Poorly Differentiated Pancreatic Neuroendocrine Carcinoma. 61
32138704 2020
6
A phase II trial of everolimus in patients with advanced pancreatic neuroendocrine carcinoma refractory or intolerant to platinum-containing chemotherapy (NECTOR trial). 61
31986515 2020
7
The Eighth Edition of the American Joint Committee on Cancer Distant Metastases Stage Classification for Metastatic Pancreatic Neuroendocrine Tumors Might Be Feasible for Metastatic Pancreatic Ductal Adenocarcinomas. 61
31357196 2020
8
[A Case of Pancreatic Neuroendocrine Carcinoma Presenting Multiple Liver Metastasis as an Initial Manifestation for Which Diagnosis Confirmation Was Difficult]. 61
32156886 2019
9
A Clinicopathologic and Molecular Update of Pancreatic Neuroendocrine Neoplasms With a Focus on the New World Health Organization Classification. 61
31509453 2019
10
LARGE CELL METASTATIC PANCREATIC NEUROENDOCRINE CARCINOMA TREATED WITH SOMATOSTATIN ANALOGUES - CASE REPORT AND LITERATURE REVIEW. 61
32010361 2019
11
Hepatobiliary and Pancreatic: A procalcitonin-secreting and calcitonin-secreting pancreatic neuroendocrine carcinoma. 61
30663800 2019
12
Surgery for Pancreatic Neuroendocrine Tumor G3 and Carcinoma G3 Should be Considered Separately. 61
30863939 2019
13
Surgical resection of the primary tumor leads to prolonged survival in metastatic pancreatic neuroendocrine carcinoma. 61
30898132 2019
14
Textural analysis on contrast-enhanced CT in pancreatic neuroendocrine neoplasms: association with WHO grade. 61
30182253 2019
15
Adrenocorticotropin Hormone Secreting Carcinoma of the Pancreas: A Case Report. 61
31236541 2019
16
Neoplasms of the Neuroendocrine Pancreas: An Update in the Classification, Definition, and Molecular Genetic Advances. 61
29912000 2019
17
[A Case of Successful Treatment of Recurrent Liver Metastases from Mixed Adenoneuroendocrine Carcinoma of the Pancreas with Everolimus Administration]. 61
30587736 2018
18
The Levels of Tumor Markers in Pancreatic Neuroendocrine Carcinoma and Their Values in Differentiation Between Pancreatic Neuroendocrine Carcinoma and Pancreatic Ductal Adenocarcinoma. 61
30308534 2018
19
TFE3 is a diagnostic marker for solid pseudopapillary neoplasms of the pancreas. 61
30030118 2018
20
Cutaneous metastases of pancreatic neuroendocrine carcinoma. 61
30246953 2018
21
Surgical resection of primary tumor is prolonged survival in metastatic pancreatic neuroendocrine carcinoma. 61
32137215 2018
22
A phase II study of everolimus in patients with unresectable pancreatic neuroendocrine carcinoma refractory or intolerant to platinum-containing chemotherapy. 61
32137201 2018
23
The differentiation of pancreatic neuroendocrine carcinoma from pancreatic ductal adenocarcinoma: the values of CT imaging features and texture analysis. 61
30333055 2018
24
Impressive Response to Tandem Treatment With [90Y]DOTATOC and [177Lu]DOTATOC in Grade 3 Pancreatic Neuroendocrine Carcinoma. 61
29742602 2018
25
Pancreatic neuroendocrine carcinomas reveal a closer relationship to ductal adenocarcinomas than to neuroendocrine tumors G3. 61
29596894 2018
26
Metachronous gastric metastasis from lung primary, with synchronous pancreatic neuroendocrine carcinoma. 61
29988660 2018
27
An Advanced Well-differentiated Pancreatic Neuroendocrine Carcinoma (NET-G3) Associated with Von Hippel-Lindau Disease. 61
29491307 2018
28
Surgical resection of primary tumor site is associated with prolonged survival in metastatic pancreatic neuroendocrine carcinoma. 61
32177106 2018
29
Selective internal radiation therapy: an effective treatment for hormonal syndromes in pancreatic neuroendocrine tumors. 61
31293777 2018
30
[Conversion Surgery after Etoposide/Cisplatin(EP)Therapy for Huge Pancreatic Neuroendocrine Carcinoma - A Case Report]. 61
29650928 2018
31
Laparoscopic Resection of a Pancreatic β Cell Tumor in a Dog. 61
28892425 2017
32
Differences between Grades G1 and G2 Hypovascular Pancreatic Neuroendocrine Tumors and Pancreatic Neuroendocrine Carcinoma. 61
28926309 2017
33
Rb Loss and KRAS Mutation Are Predictors of the Response to Platinum-Based Chemotherapy in Pancreatic Neuroendocrine Neoplasm with Grade 3: A Japanese Multicenter Pancreatic NEN-G3 Study. 61
28455360 2017
34
Differentiation of pancreatic neuroendocrine carcinoma from pancreatic ductal adenocarcinoma using magnetic resonance imaging: The value of contrast-enhanced and diffusion weighted imaging. 61
28487490 2017
35
Pancreatic neuroendocrine carcinoma with exocrine differentiation in a young cat. 61
28363254 2017
36
Clinical outcomes and prognostic factors of resected pancreatic neuroendocrine neoplasms: A single-center experience in China. 61
28521422 2017
37
Characterization of single lesion nonfunctioning pancreatic neuroendocrine carcinoma via computed tomography. 61
28454379 2017
38
The prognostic influence of the proliferative discordance in metastatic pancreatic neuroendocrine carcinoma revealed by peptide receptor radionuclide therapy: Case report and review of literature. 61
28178157 2017
39
Targeted Therapies Provide Treatment Options for Poorly Differentiated Pancreatic Neuroendocrine Carcinomas. 61
27838688 2017
40
Pancreatic neuroendocrine neoplasms at magnetic resonance imaging: comparison between grade 3 and grade 1/2 tumors. 61
28331340 2017
41
[Surgical treatment and prognosis of pancreatic neuroendocrine carcinoma]. 61
27998470 2016
42
Granulomatous Insulitis as a Cause of Acute-Onset Insulin-Dependent Diabetes Mellitus in a Patient With a Pancreatic Endocrine Carcinoma. 61
27160433 2016
43
Clinical characteristics and management of insulin-producing neuroendocrine carcinomas. 61
27821028 2016
44
Surgical Treatment as a Principle for Patients with High-Grade Pancreatic Neuroendocrine Carcinoma: A Nordic Multicenter Comparative Study. 61
26678407 2016
45
Metronomic temozolomide as second line treatment for metastatic poorly differentiated pancreatic neuroendocrine carcinoma. 61
27142424 2016
46
Pathology and Surgical Treatment of High-Grade Pancreatic Neuroendocrine Carcinoma: an Evolving Landscape. 61
26984415 2016
47
A malignant cause of hypoglycaemia: a metastatic insulin-secreting pancreatic neuroendocrine carcinoma. 61
26994053 2016
48
A giant non-functioning pancreatic neuroendocrine carcinoma founded as an incidentaloma successfully treated with pancreatoduodenectomy. 61
27713785 2016
49
Intraductal Tubulopapillary Neoplasm of the Pancreas Masquerading as Pancreatic Neuroendocrine Carcinoma: Review of the Literature with a Case Report. 61
27459312 2016
50
Long-term outcomes and prognostic factors in 78 Japanese patients with advanced pancreatic neuroendocrine neoplasms: a single-center retrospective study. 61
26378090 2015

Variations for Pancreatic Endocrine Carcinoma

Expression for Pancreatic Endocrine Carcinoma

Search GEO for disease gene expression data for Pancreatic Endocrine Carcinoma.

Pathways for Pancreatic Endocrine Carcinoma

GO Terms for Pancreatic Endocrine Carcinoma

Cellular components related to Pancreatic Endocrine Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.56 SST SERPINA3 PTHLH PPY GCG GAST
2 neuron projection GO:0043005 9.55 SYP SSTR5 SSTR3 SSTR2 NCAM1
3 extracellular region GO:0005576 9.32 SST SPINK5 SERPINA3 PTHLH PPY NCAM1

Biological processes related to Pancreatic Endocrine Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 negative regulation of cell proliferation GO:0008285 9.63 SSTR5 SSTR3 SSTR2 SST PTHLH MEN1
2 neuropeptide signaling pathway GO:0007218 9.62 SSTR5 SSTR3 SSTR2 PPY
3 G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger GO:0007187 9.58 SSTR5 SSTR3 SSTR2
4 G protein-coupled receptor signaling pathway GO:0007186 9.56 SSTR5 SSTR3 SSTR2 SST PTHLH PPY
5 osteoblast development GO:0002076 9.43 PTHLH MEN1
6 cellular response to glucocorticoid stimulus GO:0071385 9.43 SSTR5 SSTR3 SSTR2
7 hormone-mediated apoptotic signaling pathway GO:0008628 9.37 SSTR3 SST
8 somatostatin signaling pathway GO:0038170 8.8 SSTR5 SSTR3 SSTR2

Molecular functions related to Pancreatic Endocrine Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 peptide binding GO:0042277 9.43 SSTR5 SSTR3 SSTR2
2 hormone activity GO:0005179 9.35 SST PTHLH PPY GCG GAST
3 neuropeptide binding GO:0042923 9.33 SSTR5 SSTR3 SSTR2
4 somatostatin receptor activity GO:0004994 8.8 SSTR5 SSTR3 SSTR2

Sources for Pancreatic Endocrine Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....